Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1316 + Chemo + RT in ES-SCLC
NCT04562337Phase 2Active, not recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Oct 2020
- Primary completion
- Oct 2024
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adebrelimab in small cell lung cancer (SCLC), sponsored by Shandong Cancer Hospital. Primary endpoint: Overall Survival at 36 months. Started Oct 2020; status: active, not recruiting.
02
Drugs
adebrelimab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT04562337.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04562337.